Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis
NCT ID: NCT02271204
Last Updated: 2014-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
700 participants
OBSERVATIONAL
2009-03-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis
NCT01290094
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia.
NCT00545207
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
NCT02598440
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
NCT01128257
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
NCT00129623
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ibandronic acid
As prescribed by physician
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients had no contraindication for bisphosphonates
* Patients had been naive for ibandronate therapy
* Patients who have signed informed consent and are willing to share their data for data analysis
Exclusion Criteria
* Hypersensitivity to any component of the bisphosphonates Ibandronate;
* Administration of any investigational drug within 30 days preceding the first dose of the study drug.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clinic for Orthopedic Surgery, Skopje
UNKNOWN
General Hospital, Kumanovo
UNKNOWN
General Hospital, Struga
UNKNOWN
Medical Faculty, Institute for Epidemiology and Biostatistics, Skopje
UNKNOWN
Clinic of Endocrinology and Metabolic Disorders, Macedonia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML21741
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.